Potential oral drug for rheumatoid arthritis discoveredCH-1504, considered by many as a potential oral drug for rheumatoid arthritis (RA), can motivate women to treat their condition earlier because it is less difficult than currently-available treatment options.

Chelsea Therapeutics, a pharmaceutical company specializing in treatment for rheumatoid arthritis and other immunological diseases, is currently on a developing spree to formulate an oral anti-inflammatory drug and conducting Phase I clinical trials in the UK with an aim to provide an amicable solution for this condition that is more prevalent in women and develops between ages of 35 and 50.

Dr. M. Gopal Nair, a professor and vice-chairman at the department of Biochemistry and Molecular Biology at the University of South Alabama, initially developed the CH-1504 therapy.